Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.